164 related articles for article (PubMed ID: 7675641)
1. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I].
Feine U; Lietzenmayer R; Hanke JP; Wöhrle H; Müller-Schauenburg W
Nuklearmedizin; 1995 Aug; 34(4):127-34. PubMed ID: 7675641
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
3. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
4. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
5. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
Giammarile F; Hafdi Z; Bournaud C; Janier M; Houzard C; Desuzinges C; Itti R; Sassolas G; Borson-Chazot F
Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
[TBL] [Abstract][Full Text] [Related]
6. [PET-FDG in thyroid cancer with high thyroglobulin levels and negative 131-I scan. A case report].
Ortega F; Maldonado A; Marañes P; Montz R; Pérez-Castejón MJ; Melgarejo M; Ruiz JA; Carreras JL
Rev Esp Med Nucl; 1999; 18(1):50-4. PubMed ID: 10074219
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
[TBL] [Abstract][Full Text] [Related]
8. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose.
Joensuu H; Ahonen A
J Nucl Med; 1987 May; 28(5):910-4. PubMed ID: 3572549
[TBL] [Abstract][Full Text] [Related]
9. Whole-body scintigraphy with 99Tcm-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinoma.
Fridrich L; Messa C; Landoni C; Lucignani G; Moncayo R; Kendler D; Riccabona G; Fazio F
Nucl Med Commun; 1997 Jan; 18(1):3-9. PubMed ID: 9061694
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Eur J Nucl Med; 1997 Nov; 24(11):1342-8. PubMed ID: 9371865
[TBL] [Abstract][Full Text] [Related]
12. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
[TBL] [Abstract][Full Text] [Related]
13. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
Grünwald F; Schomburg A; Bender H; Klemm E; Menzel C; Bultmann T; Palmedo H; Ruhlmann J; Kozak B; Biersack HJ
Eur J Nucl Med; 1996 Mar; 23(3):312-9. PubMed ID: 8599963
[TBL] [Abstract][Full Text] [Related]
15. Determination of malignancy of thyroid nodules with positron emission tomography.
Bloom AD; Adler LP; Shuck JM
Surgery; 1993 Oct; 114(4):728-34; discussion 734-5. PubMed ID: 8211687
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
17. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Deandreis D; Al Ghuzlan A; Leboulleux S; Lacroix L; Garsi JP; Talbot M; Lumbroso J; Baudin E; Caillou B; Bidart JM; Schlumberger M
Endocr Relat Cancer; 2011 Feb; 18(1):159-69. PubMed ID: 21118976
[TBL] [Abstract][Full Text] [Related]
18. In follicular thyroid carcinoma we found,
Xiao L; Zhang WJ; Li L
Hell J Nucl Med; 2019; 22(2):140-141. PubMed ID: 31273357
[No Abstract] [Full Text] [Related]
19. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
20. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide.
Scott GC; Meier DA; Dickinson CZ
J Nucl Med; 1995 Oct; 36(10):1843-5. PubMed ID: 7562053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
